60 Degrees Pharma's B-Free Babesiosis Trial Clears Initial Safety Review, Advances After DSMB Recommendation
60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP, SXTPW))) ("60 Degrees Pharma" or the "Company"), a pharmaceutical company focused on developing new medicines for vector-borne disease, announced today that the independent Data Safety Monitoring Board has recommended continuation of the B-Free chronic babesiosis study (